Trade Summary

4 days ago, Reardon Andrew, serving as CLO, Secretary at Ligand Pharmaceuticals Inc (LGND), sold 5,000 shares at $231.31 per share, for a total transaction value of $1,156,556.00. Following this transaction, Reardon Andrew now holds 41,382 shares of LGND.

This sale represents a 11.00% decrease in Reardon Andrew's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, May 1, 2026 and publicly disclosed via SEC Form 4 filing on Monday, May 4, 2026, 3 days after the trade was made.

Ligand Pharmaceuticals Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.